Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:ANABNASDAQ:VTYXNASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.40-2.2%$3.34$2.71▼$4.73$650.24M1.23963,845 shs307,362 shsANABAnaptysBio$22.84-2.4%$21.17$12.21▼$41.31$669.86M-0.26636,182 shs112,035 shsVTYXVentyx Biosciences$2.23-6.1%$1.62$0.78▼$3.39$158.33M0.851.37 million shs560,858 shsXERSXeris Biopharma$4.54-1.0%$4.57$2.03▼$6.07$709.18M0.711.99 million shs678,702 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-3.07%+8.10%+5.79%+15.28%ANABAnaptysBio0.00%-0.09%+10.85%+36.94%+2.18%VTYXVentyx Biosciences0.00%-4.82%+49.06%+79.55%-13.82%XERSXeris Biopharma0.00%+3.62%-9.84%-21.17%+115.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.2946 of 5 stars3.50.00.00.03.22.50.6ANABAnaptysBio2.0309 of 5 stars3.40.00.00.03.51.70.6VTYXVentyx Biosciences2.4183 of 5 stars3.41.00.00.03.02.50.6XERSXeris Biopharma4.2127 of 5 stars3.42.00.04.23.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5062.00% UpsideANABAnaptysBio 2.80Moderate Buy$42.3885.53% UpsideVTYXVentyx Biosciences 2.75Moderate Buy$10.00349.44% UpsideXERSXeris Biopharma 2.83Moderate Buy$6.2537.82% UpsideCurrent Analyst Ratings BreakdownLatest VTYX, XERS, ABUS, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/9/2025XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/26/2025ANABAnaptysBioJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M105.39N/AN/A$0.51 per share6.66ANABAnaptysBio$91.28M7.35N/AN/A$2.33 per share9.80VTYXVentyx BiosciencesN/AN/AN/AN/A$3.59 per shareN/AXERSXeris Biopharma$203.07M3.49N/AN/A($0.20) per share-22.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)ANABAnaptysBio-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)VTYXVentyx Biosciences-$135.12M-$1.75N/AN/AN/AN/A-47.45%-43.49%8/14/2025 (Estimated)XERSXeris Biopharma-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)Latest VTYX, XERS, ABUS, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/8/2025Q1 2025VTYXVentyx Biosciences-$0.48-$0.39+$0.09-$0.39N/AN/A5/8/2025Q1 2025XERSXeris Biopharma-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus Biopharma0.046.016.01ANABAnaptysBioN/A8.258.25VTYXVentyx BiosciencesN/A19.5719.57XERSXeris BiopharmaN/A1.721.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ANABAnaptysBioN/AVTYXVentyx Biosciences97.88%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ANABAnaptysBio33.50%VTYXVentyx Biosciences14.49%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableANABAnaptysBio10029.38 million19.54 millionOptionableVTYXVentyx Biosciences3071.16 million60.85 millionOptionableXERSXeris Biopharma290156.38 million146.27 millionOptionableVTYX, XERS, ABUS, and ANAB HeadlinesRecent News About These CompaniesXeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term InvestingJune 18 at 10:17 AM | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying ActivityJune 18 at 1:11 AM | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying ActivityJune 17 at 10:18 AM | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 SharesJune 17 at 4:49 AM | insidertrades.comKevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) StockJune 16, 2025 | marketbeat.comLeerink Partnrs Estimates Xeris Biopharma FY2025 EarningsJune 9, 2025 | marketbeat.comLeerink Partnrs Cuts Earnings Estimates for Xeris BiopharmaJune 6, 2025 | marketbeat.comXeris Biopharma touts ambitious growth plan, promising hypothyroidism drugJune 4, 2025 | chicagobusiness.comMackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 4, 2025 | marketbeat.comXeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayJune 3, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What HappenedJune 3, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsJune 3, 2025 | marketbeat.comNuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 1, 2025 | marketbeat.comMillennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 29, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 28, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street ZenMay 24, 2025 | marketbeat.comXeris Announces Details for Analyst & Investor DayMay 20, 2025 | businesswire.comStonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 20, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.May 20, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTYX, XERS, ABUS, and ANAB Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.40 -0.08 (-2.16%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.AnaptysBio NASDAQ:ANAB$22.84 -0.55 (-2.35%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Ventyx Biosciences NASDAQ:VTYX$2.22 -0.15 (-6.12%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.Xeris Biopharma NASDAQ:XERS$4.54 -0.05 (-0.98%) As of 01:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Dan Ives Just Unveiled His AI ETF—Does It Live Up to the Hype? Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
